Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -41.96M | -36.12M | -14.70M | -8.08M | EBIT |
-525.21M | -479.03M | -420.62M | -215.27M | -81.02M | EBITDA |
-525.21M | -400.74M | -373.37M | -29.86M | -1.65B | Net Income Common Stockholders |
-477.86M | -445.14M | -403.19M | -47.54M | -121.45M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
910.77M | 1.07B | 1.06B | 1.45B | 997.55M | Total Assets |
1.32B | 1.50B | 1.48B | 1.72B | 1.07B | Total Debt |
93.54M | 100.63M | 105.42M | 77.37M | 12.46M | Net Debt |
-47.33M | -41.89M | -129.98M | -243.33M | -100.75M | Total Liabilities |
164.55M | 161.80M | 155.86M | 107.06M | 23.59M | Stockholders Equity |
1.16B | 1.34B | 1.32B | 1.61B | 1.04B |
Cash Flow | Free Cash Flow | |||
-336.69M | -324.54M | -376.87M | -255.09M | -85.36M | Operating Cash Flow |
-274.56M | -240.03M | -218.02M | -127.91M | -61.26M | Investing Cash Flow |
128.87M | -152.53M | 124.12M | -385.83M | -802.65M | Financing Cash Flow |
144.03M | 300.21M | 8.60M | 736.56M | 953.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $12.39B | 10.47 | 1.07% | 3.58% | 1.64% | -18.33% | |
48 Neutral | $194.73M | ― | -21.13% | ― | 15.67% | -45.59% | |
46 Neutral | $2.32B | ― | -38.29% | ― | ― | 2.40% | |
44 Neutral | $1.42B | ― | -88.04% | ― | 1429.35% | -36.13% | |
43 Neutral | $1.58B | ― | -90.88% | ― | -29.45% | -10.79% |
QuantumScape Corporation has announced the appointment of Dennis Segers and Dr. Günther Mendl to its Board of Directors. Segers, a veteran in the semiconductor industry, will also serve as Chairman starting January 1, 2025, succeeding Jagdeep Singh, who is retiring. Dr. Mendl, who has extensive experience in battery technology, joins as a representative of Volkswagen Group. Both directors are part of the company’s standard compensation program, though Dr. Mendl has waived his compensation rights.